{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:49:53Z","timestamp":1791416993874,"version":"4.3.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02249-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:25:13Z","timestamp":1783913113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical recurrence following definitive treatment of prostate cancer in Brazil: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-5635","authenticated-orcid":false,"given":"Murilo","family":"de Almeida Luz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatas","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner Eduardo","family":"Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bomfim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Carolina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2249_CR1","unstructured":"National Cancer Institute (2023) Cancer Stat Facts: Common Cancer Sites. https:\/\/seer.cancer.gov\/statfacts\/html\/common.html#:~:text=Prostate%20cancer%20is%20the%20leading,an%20estimated%20234%2C580%20new%20cases. Accessed 2 Dec 2024."},{"key":"2249_CR2","unstructured":"GLOBOCON (2022) Global Cancer Observatory (Prostate cancer). https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/27-prostate-fact-sheet.pdf. Accessed 2 Dec 2024."},{"key":"2249_CR3","unstructured":"Instituto Nacional de C\u00e2ncer \u2013 INCA (2023) Estat\u00edsticas de cancer. https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/numeros\/. Accessed 2 Dec 2024."},{"key":"2249_CR4","unstructured":"World Health Organization. International Agency for Research on Cancer (2022) Estimated number of new cases in 2022, Brazil, males, all ages. https:\/\/gco.iarc.fr\/today\/home. Accessed 2 Dec 2024."},{"key":"2249_CR5","unstructured":"European Association of Urology (2024) Guidelines on prostate cancer. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.pdf. Accessed 2 Dec 2024."},{"issue":"24","key":"2249_CR6","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. J Am Med Assoc. 2017;317(24):2532\u201342. https:\/\/doi.org\/10.1001\/jama.2017.7248.","journal-title":"J Am Med Assoc"},{"issue":"6","key":"2249_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/cncr.23293","volume":"112","author":"N Suardi","year":"2008","unstructured":"Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008;112(6):1254\u201363. https:\/\/doi.org\/10.1002\/cncr.23293.","journal-title":"Cancer"},{"issue":"4","key":"2249_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer\u2013specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc. 2005;294(4):433\u20139. https:\/\/doi.org\/10.1001\/jama.294.4.433.","journal-title":"J Am Med Assoc"},{"issue":"3","key":"2249_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00345-006-0058-2","volume":"24","author":"FK Chun","year":"2006","unstructured":"Chun FK, Graefen M, Zacharias M, Haese A, Steuber T, Schlomm T, et al. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol. 2006;24(3):273\u201380. https:\/\/doi.org\/10.1007\/s00345-006-0058-2.","journal-title":"World J Urol"},{"issue":"16_suppl","key":"2249_CR10","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1200\/JCO.2022.40.16_suppl.5090","volume":"40","author":"KD Stensland","year":"2022","unstructured":"Stensland KD, Caram MV, Burns JA, Sparks JB, Shin C, Zaslavsky A, et al. Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments. J Clin Oncol. 2022;40(16_suppl):5090. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5090.","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"2249_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1200\/JCO.2023.41.6_suppl.393","volume":"41","author":"D Escobar","year":"2023","unstructured":"Escobar D, Wang L, Banton J, Cowan JE, Washington SL, Mohamad O, et al. Long-term rates of biochemical recurrence after primary external beam radiation therapy (EBRT) for prostate cancer. J Clin Oncol. 2023;41(6_suppl):393. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.393.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2249_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/01.ju.0000045749.90353.c7","volume":"169","author":"M Han","year":"2003","unstructured":"Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517\u201323. https:\/\/doi.org\/10.1097\/01.ju.0000045749.90353.c7.","journal-title":"J Urol"},{"issue":"1","key":"2249_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","volume":"164","author":"CL Amling","year":"2000","unstructured":"Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164(1):101\u20135. https:\/\/doi.org\/10.1016\/S0022-5347(05)67457-5.","journal-title":"J Urol"},{"issue":"1","key":"2249_CR14","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1038\/s41598-022-16395-w","volume":"12","author":"JF Su\u00e1rez","year":"2022","unstructured":"Su\u00e1rez JF, Zamora V, Garin O, Guti\u00e9rrez C, Pont \u00c0, Pardo Y, et al. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Sci Rep. 2022;12(1):12589. https:\/\/doi.org\/10.1038\/s41598-022-16395-w.","journal-title":"Sci Rep"},{"issue":"2","key":"2249_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27(2):192\u2013201. https:\/\/doi.org\/10.1038\/s41391-023-00712-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"2249_CR16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1055-9965.Epi-19-1616","volume":"29","author":"EM Rencsok","year":"2020","unstructured":"Rencsok EM, Bazzi LA, McKay RR, Huang FW, Friedant A, Vinson J, et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1374\u201380. https:\/\/doi.org\/10.1158\/1055-9965.Epi-19-1616.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2249_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3332\/ecancer.2023.1629","volume":"17","author":"SA Halaseh","year":"2023","unstructured":"Halaseh SA, Al-Karadsheh A, Mukherji D, Alhjahaja A, Farkouh A, Al-Ibraheem A, et al. Prostate cancer clinical trials in low- and middle-income countries. Ecancermedicalscience. 2023;17:1629. https:\/\/doi.org\/10.3332\/ecancer.2023.1629.","journal-title":"Ecancermedicalscience"},{"issue":"9","key":"2249_CR18","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, Abbadi A, Remmers S, Bj\u00f6rnebo L, Bogdanovic D, Martini A, et al. Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw Open. 2023;6(9):e2332900. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.32900.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2249_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2023.05.038","volume":"85","author":"F Preisser","year":"2024","unstructured":"Preisser F, Abrams-Pompe RS, Stelwagen PJ, B\u00f6hmer D, Zattoni F, Magli A, et al. European Association of Urology biochemical recurrence risk classification as a decision tool for salvage radiotherapy - a multicenter study. Eur Urol. 2024;85(2):164\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.038.","journal-title":"Eur Urol"},{"key":"2249_CR20","doi-asserted-by":"publisher","first-page":"110215","DOI":"10.1016\/j.radonc.2024.110215","volume":"194","author":"S Scharl","year":"2024","unstructured":"Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Koerber SA, et al. European Association of Urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiother Oncol. 2024;194:110215. https:\/\/doi.org\/10.1016\/j.radonc.2024.110215.","journal-title":"Radiother Oncol"},{"issue":"5","key":"2249_CR21","doi-asserted-by":"publisher","first-page":"298.e1","DOI":"10.1016\/j.urolonc.2020.12.023","volume":"39","author":"S Pak","year":"2021","unstructured":"Pak S, Lee D-E, You D, Jeong IG, Joung JY, Lee K-H, et al. Validation of the European Association of Urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement. Urol Oncol Semin Orig Investig. 2021;39(5):298.e1-e6. https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.023.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"3","key":"2249_CR22","doi-asserted-by":"publisher","first-page":"119.e11","DOI":"10.1016\/j.urolonc.2015.09.012","volume":"34","author":"K Boehm","year":"2016","unstructured":"Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, et al. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Urol Oncol. 2016;34(3):119.e11-18. https:\/\/doi.org\/10.1016\/j.urolonc.2015.09.012.","journal-title":"Urol Oncol"},{"issue":"45","key":"2249_CR23","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.3346\/jkms.2018.33.e285","volume":"33","author":"DK Kim","year":"2018","unstructured":"Kim DK, Koo KC, Lee KS, Hah YS, Rha KH, Hong SJ, et al. Time to disease recurrence is a predictor of metastasis and mortality in patients with high-risk prostate cancer who achieved undetectable prostate-specific antigen following robot-assisted radical prostatectomy. J Korean Med Sci. 2018;33(45):e285. https:\/\/doi.org\/10.3346\/jkms.2018.33.e285.","journal-title":"J Korean Med Sci"},{"issue":"4","key":"2249_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965\u201374. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2249_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/iju.13514","volume":"25","author":"Y Murata","year":"2018","unstructured":"Murata Y, Tatsugami K, Yoshikawa M, Hamaguchi M, Yamada S, Hayakawa Y, et al. Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer. Int J Urol. 2018;25(3):284\u20139. https:\/\/doi.org\/10.1111\/iju.13514.","journal-title":"Int J Urol"},{"issue":"10288","key":"2249_CR26","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00651-0","volume":"397","author":"AB Jani","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S, Halkar R, Goodman M, Rossi PJ, et al. 68Ga-PSMA-11 PET\/CT imaging versus conventional imaging for radiotherapy treatment planning in patients with biochemically recurrent prostate cancer after radical prostatectomy (EMPIRE-1): a phase 2\/3 randomised controlled trial. Lancet. 2021;397(10288):1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(21)00651-0.","journal-title":"Lancet"},{"issue":"20","key":"2249_CR27","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/jco.23.00155","volume":"41","author":"KS Virgo","year":"2023","unstructured":"Virgo KS, Rumble RB, Talcott J. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol. 2023;41(20):3652\u20136. https:\/\/doi.org\/10.1200\/jco.23.00155.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2249_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/cancers16040764","volume":"16","author":"A Sciarra","year":"2024","unstructured":"Sciarra A, Santarelli V, Salciccia S, Moriconi M, Basile G, Santodirocco L, et al. How the management of biochemical recurrence in prostate cancer will be modified by the concept of anticipation and incrementation of therapy. Cancers (Basel). 2024;16(4):764. https:\/\/doi.org\/10.3390\/cancers16040764.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"2249_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Pienta KJ, Rezazadeh Kalebasty A, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303765.","journal-title":"N Engl J Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02249-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:03:36Z","timestamp":1791414216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02249-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02249-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee \u201cComit\u00ea de \u00c9tica em Pesquisa da Liga Paranaense de Combate ao C\u00e2ncer\u201d under the registry number: 65545822.9.0000.0098. Considering all unidentified and retrospective data, the ethics committee waived the individual additional consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors report administrative support, article publishing charges, and writing assistance were provided by Astellas Pharma. Murilo de Almeida Luz reports relationships with Astellas, Janssen, and Bayer that include: consulting or advisory and speaking and lecture fees. Murilo de Almeida Luz reports relationships with Merck, Janssen, Astellas, and Bayer that include: travel reimbursement. Marcos Freire, Sarah C. Gon\u00e7alves, Giovanni Bomfim, and Roberto Soler each report a relationship with Astellas that includes: employment. Ronald Kool reports relationships with Janssen, Adium, Bayer, and Merck that include: speaking and lecture fees. Ronald Kool reports relationships with Bayer, Adium, and Janssen that include: travel reimbursement. Ronald Kool reports relationships with Adium and Janssen that include: a consulting or advisory role. Jonatas Pereira reports relationships with Astellas, Janssen, Bayer, and AstraZeneca that include: speaking and lecture fees. Jonatas Pereira reports relationships with Janssen, Bayer, AstraZeneca, and Zodiac that include: travel reimbursement. Jonatas Pereira reports a relationship with Janssen that includes: a consulting or advisory role. Wagner Eduardo Matheus reports relationships with Janssen Brasil, Astellas Farma Brasil, and Bayer that include: speaking and lecture fees. Wagner Eduardo Matheus reports a relationship with Janssen that includes: travel reimbursement. Wagner Eduardo Matheus reports a relationship with Brazilian Urological Society that includes: board membership.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"236"}}